Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
08
10
2020
accepted:
15
12
2020
pubmed:
20
12
2020
medline:
15
4
2021
entrez:
19
12
2020
Statut:
ppublish
Résumé
Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19). Its benefit-risk ratio is still being explored because data in the field are rather scant. A decrease of the creatinine clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance. Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance postmarketing data. An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir). The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P < 0.0001]) that of comparative drugs. Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal function should prevail before and during treatment with remdesivir in COVID-19.
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1021-1024Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
Jorgensen, S.C.J., Kebriaei, R. & Dresser, L.D. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacother. J. Hum. Pharmacol. Drug Ther. 40, 659-671 (2020).
Tchesnokov, E.P., Feng, J.Y., Porter, D.P. & Götte, M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326 (2019).
Agostini, M.L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-18 (2018).
FDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. FDA <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment> (2020).
EMA. First COVID-19 treatment recommended for EU authorisation. European Medicines Agency <https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation> (2020).
Mahase, E. Covid-19: remdesivir probably reduces recovery time, but evidence is uncertain, panel finds. BMJ 370, m3049 (2020).
Fan, Q., Zhang, B., Ma, J. & Zhang, S. Safety profile of the antiviral drug remdesivir: an update. Biomed. Pharmacother. 130, 110532 (2020).
European Medicines Agency. EMA - Summary on compassionate use - Remdesivir <https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf> (2020).
Luke, D.R., Tomaszewski, K., Damle, B. & Schlamm, H.T. Review of the basic and clinical pharmacology of sulfobutylether-β-cydodextrin (SBECD). J. Pharm. Sci. 99, 3291-3301 (2010).
Adamsick, M.L. et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J. Am. Soc. Nephrol. 31, 1384-1386 (2020).
Fisher, M. et al. AKI in hospitalized patients with and without COVID-19: a comparison study. J. Am. Soc. Nephrol. 31, 2145-2157 (2020).
Goldman, J.D. et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N. Engl. J. Med. 383, 1827-1837 (2020).
Antinori, S. et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol. Res. 158, 104899 (2020).
Beigel, J.H. et al. Remdesivir for the treatment of Covid-19 - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764.
Spinner, C.D. et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324, 1048 (2020).
Lindquist, M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf. J. 42, 409-419 (2008).
Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315-321 (1998).
Standardised MedDRA Queries | MedDRA <https://www.meddra.org/standardised-meddra-queries>.
Egberts, A.C.G., Meyboom, R.H.B. & van Puijenbroek, E.P. Use of measures of disproportionality in pharmacovigilance. Drug Saf. 25, 453-458 (2002).
EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 2020. European Medicines Agency <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october-2020> (2020).
Puelles, V.G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590-592 (2020).
Montastruc, F., Thuriot, S. & Durrieu, G. Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19). Clin. Gastroenterol. Hepatol. 18, 2835-2836 (2020).
Fung, J., Seto, W.-K., Lai, C.-L. & Yuen, M.-F. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment: extrahepatic effects of antiviral drugs. J. Gastroenterol. Hepatol. 29, 428-434 (2014).
Izzedine, H., Launay-Vacher, V. & Deray, G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 45, 804-817 (2005).
Hennessy, S. Disproportionality analyses of spontaneous reports. Pharmacoepidemiol. Drug Saf. 13, 503-504 (2004).
WHO Collaborating Centre for International Drug Monitoring. Descriptive analysis of COVID-19-related spontaneous reports from VigiBase: interim results <https://www.who.int/medicines/regulation/medicines-safety/covid-19-pv-report-10.pdf> (2020).